<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ruan J</submitter><funding>NIDDK NIH HHS</funding><funding>NIA NIH HHS</funding><funding>National Institute of Diabetes and Digestive and Kidney Diseases</funding><funding>NHLBI NIH HHS</funding><funding>National Heart, Lung, and Blood Institute</funding><funding>National Institute on Aging</funding><pagination>97</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9719645</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Unlike other proteins that exhibit a diffusion pattern after intracerebral injection, laminin displays a vascular pattern. It remains unclear if this unique vascular pattern is caused by laminin-receptor interaction or laminin self-assembly.&lt;h4>Methods&lt;/h4>We compared the distribution of various wild-type laminin isoforms in the brain after intracerebral injection. To determine what causes the unique vascular pattern of laminin in the brain, laminin mutants with impaired receptor-binding and/or self-assembly activities and function-blocking antibodies to laminin receptors were used. In addition, the dynamics of laminin distribution and elimination were examined at multiple time points after intracerebral injection.&lt;h4>Results&lt;/h4>We found that β2-containing laminins had higher affinity for the vessels compared to β1-containing laminins. In addition, laminin mutants lacking receptor-binding domains but not that lacking self-assembly capability showed substantially reduced vascular pattern. Consistent with this finding, dystroglycan (DAG1) function-blocking antibody significantly reduced the vascular pattern of wild-type laminin-111. Although failed to affect the vascular pattern when used alone, integrin-β1 function-blocking antibody further decreased the vascular pattern when combined with DAG1 antibody. EDTA, which impaired laminini-DAG1 interaction by chelating Ca&lt;sup>2+&lt;/sup>, also attenuated the vascular pattern. Immunohistochemistry revealed that laminins were predominantly located in the perivascular space in capillaries and venules/veins but not arterioles/arteries. The time-course study showed that laminin mutants with impaired receptor-engaging activity were more efficiently eliminated from the brain compared to their wild-type counterparts. Concordantly, significantly higher levels of mutant laminins were detected in the cerebral-spinal fluid (CSF).&lt;h4>Conclusions&lt;/h4>These findings suggest that intracerebrally injected laminins are enriched in the perivascular space in a receptor (DAG1/integrin)-dependent rather than self-assembly-dependent manner and eliminated from the brain mainly via the perivascular clearance system.</pubmed_abstract><journal>Fluids and barriers of the CNS</journal><pubmed_title>Exogenous laminin exhibits a unique vascular pattern in the brain via binding to dystroglycan and integrins.</pubmed_title><pmcid>PMC9719645</pmcid><funding_grant_id>R01 DK036425</funding_grant_id><funding_grant_id>R21 AG073862</funding_grant_id><funding_grant_id>RF1 AG065345</funding_grant_id><funding_grant_id>R21 AG064422</funding_grant_id><funding_grant_id>R01 HL146574</funding_grant_id><funding_grant_id>R01HL146574</funding_grant_id><funding_grant_id>RF1AG065345</funding_grant_id><funding_grant_id>R01DK036425</funding_grant_id><pubmed_authors>Ruan J</pubmed_authors><pubmed_authors>Yao Y</pubmed_authors><pubmed_authors>McKee KK</pubmed_authors><pubmed_authors>Yurchenco PD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exogenous laminin exhibits a unique vascular pattern in the brain via binding to dystroglycan and integrins.</name><description>&lt;h4>Background&lt;/h4>Unlike other proteins that exhibit a diffusion pattern after intracerebral injection, laminin displays a vascular pattern. It remains unclear if this unique vascular pattern is caused by laminin-receptor interaction or laminin self-assembly.&lt;h4>Methods&lt;/h4>We compared the distribution of various wild-type laminin isoforms in the brain after intracerebral injection. To determine what causes the unique vascular pattern of laminin in the brain, laminin mutants with impaired receptor-binding and/or self-assembly activities and function-blocking antibodies to laminin receptors were used. In addition, the dynamics of laminin distribution and elimination were examined at multiple time points after intracerebral injection.&lt;h4>Results&lt;/h4>We found that β2-containing laminins had higher affinity for the vessels compared to β1-containing laminins. In addition, laminin mutants lacking receptor-binding domains but not that lacking self-assembly capability showed substantially reduced vascular pattern. Consistent with this finding, dystroglycan (DAG1) function-blocking antibody significantly reduced the vascular pattern of wild-type laminin-111. Although failed to affect the vascular pattern when used alone, integrin-β1 function-blocking antibody further decreased the vascular pattern when combined with DAG1 antibody. EDTA, which impaired laminini-DAG1 interaction by chelating Ca&lt;sup>2+&lt;/sup>, also attenuated the vascular pattern. Immunohistochemistry revealed that laminins were predominantly located in the perivascular space in capillaries and venules/veins but not arterioles/arteries. The time-course study showed that laminin mutants with impaired receptor-engaging activity were more efficiently eliminated from the brain compared to their wild-type counterparts. Concordantly, significantly higher levels of mutant laminins were detected in the cerebral-spinal fluid (CSF).&lt;h4>Conclusions&lt;/h4>These findings suggest that intracerebrally injected laminins are enriched in the perivascular space in a receptor (DAG1/integrin)-dependent rather than self-assembly-dependent manner and eliminated from the brain mainly via the perivascular clearance system.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-04T13:46:19.617Z</modification><creation>2025-02-19T04:34:17.211Z</creation></dates><accession>S-EPMC9719645</accession><cross_references><pubmed>36463265</pubmed><doi>10.1186/s12987-022-00396-y</doi></cross_references></HashMap>